



UWS Academic Portal

Evaluating functional electrical stimulation (FES) cycling on cardiovascular, musculoskeletal and functional outcomes in adults with multiple sclerosis and mobility impairment

Scally, Jennifer B.; Baker, Julien S.; Rankin, Jean; Renfrew, Linda ; Sculthorpe, Nicholas

Published in:
Multiple Sclerosis and Related Disorders

DOI:
[10.1016/j.msard.2019.101485](https://doi.org/10.1016/j.msard.2019.101485)

Published: 31/01/2020

Document Version
Peer reviewed version

[Link to publication on the UWS Academic Portal](#)

Citation for published version (APA):

Scally, J. B., Baker, J. S., Rankin, J., Renfrew, L., & Sculthorpe, N. (2020). Evaluating functional electrical stimulation (FES) cycling on cardiovascular, musculoskeletal and functional outcomes in adults with multiple sclerosis and mobility impairment: a systematic review. *Multiple Sclerosis and Related Disorders*, 37, [101485]. <https://doi.org/10.1016/j.msard.2019.101485>

General rights

Copyright and moral rights for the publications made accessible in the UWS Academic Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact pure@uws.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Evaluating Functional Electrical Stimulation (FES) Cycling on Cardiovascular, Musculoskeletal and Functional Outcomes in Adults with Multiple Sclerosis and Mobility Impairment: A systematic review

Jennifer B. Scally¹, Julien S. Baker¹, Jean Rankin¹, Linda Renfrew², Nicholas Sculthorpe¹

¹ Institute of Clinical Exercise and Health Science, School of Health and Life Sciences, University of the West of Scotland, South Lanarkshire, Scotland

² Douglas Grant Rehabilitation Unit, Ayrshire Central Hospital, Irvine, Scotland

Correspondence to: Jennifer B. Scally, Institute of Clinical Exercise and Health Science, School of Health and Life Sciences, University of the West of Scotland, South Lanarkshire, G72 0LH; jennifer.scally@uws.ac.uk; +44 (0)1698 283 100.

Abstract

Background People with Multiple Sclerosis (PwMS) are at an increased risk of diseases associated with low levels of physical activity (PA). Deconditioning may lead to an acceleration in the development of secondary complications from MS, impairing physical function and exacerbating disease progression. Functional Electrical Stimulation (FES) Cycling may provide a suitable lower limb exercise intervention for PwMS with mobility impairment. The effects of FES cycling on cardiovascular, musculoskeletal and functional outcomes for PwMS with mobility impairment are yet to be investigated to date.

Objective The objective of this review was to systematically examine the outcomes of PwMS with mobility impairment following FES cycling intervention.

Methods A systematic search of four electronic databases (MEDLINE, Web of Science, CINAHL and PEDro) from their inception to 8th January 2019 was performed. Inclusion criteria was 1) include human participants with definite diagnosis of MS 2) participants had to be aged 18 years or older 3) include participants with mobility impairment (determined as an average participant EDSS \geq 6.0) 4) evaluate FES cycling as an intervention study.

Results Initial searches found 1163 studies. 9 of which met the full inclusion criteria: 5 pre-post studies with no control group, 2 randomised controlled trials (RCTs), 1 retrospective study and 1 case study. Two studies had the same participant group and intervention but reported different outcomes. Outcome data was available for n=76 unique participants, with n=82 completing a FES cycling intervention. Of the n=4 papers with clear dropout rates, pooled dropout rate was 25.81%. Two papers reported non-significant improvements in aerobic capacity following a FES cycling intervention. Four papers reported no change in lower limb strength and two papers reported significant reductions in spasticity post training. Four studies failed to provide information regarding adverse events with the other studies reporting n=10 adverse events across 36 participants.

Conclusion Findings suggest FES cycle training may reduce CVD risk alongside trends for a reduction in spasticity post training, however the low quality of the literature precludes any definitive conclusions. FES cycle training appears to be well tolerated in PwMS with mobility impairment, with no serious adverse events.

Keywords

Multiple Sclerosis; Mobility Impairment; Functional Electrical Stimulation; Functional Electrical Stimulation Cycling; High EDSS

1. Introduction

Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the Central Nervous System (CNS) and is characterised by inflammation and neurodegeneration of the myelin sheath, axons and grey and white matter [1–5]. MS presents as symptoms of fatigue and impairment of both autonomic and somatic systems which have a deleterious impact on walking performance (and other types of physical activity), overall health, quality of life and ability to complete activities of daily living (ADLs) [2,3].

In line with these limitations, people with MS (PwMS) frequently fail to engage in the recommended amounts of moderate-to-vigorous physical activity (MVPA) necessary to accrue health benefits [4]. Moreover, studies of PwMS also report that they experience both real and perceived barriers to engaging in physical activity (PA), which when combined with reductions in physical function, may promote an inactive lifestyle resulting in physical deconditioning [5,6].

The consequences of insufficient PA and deconditioning may be particularly problematic in this cohort. PwMS are not immune to the increased risk of cardiovascular disease (CVD) occurring as a result of low levels of PA [7–9]. Indeed, deaths from secondary chronic conditions such as hypertension, increased cholesterol and diabetes are common, and the mortality rate in PwMS is estimated as being between 1.7 to 3.5 times greater than that of the general population [10,11]. In addition, deconditioning may lead to an acceleration in the development of secondary complications from MS in an interdependent manner. Deconditioning has been suggested to impair physical function and exacerbate disease progression, resulting in further reductions in levels of PA, and an associated cycle of decline in health [5,12,13]. Indeed, disease progression has been significantly correlated to reductions in aerobic capacity, muscular strength and walking performance [7,12,14,15].

Disease progression in MS is monitored and assessed utilising the Expanded

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Disability Status Scale (EDSS) [16]. The scale describes different levels of impairment and ranges from 0 to 10, with 0 representing no symptoms and 10 representing death [16]. An EDSS score of 6.0 is an identifiable milestone on the scale, whereby the individual can walk a maximum of 100m without stopping, even with the support of a unilateral assistive device [17]. As EDSS increases, PwMS are likely to participate in reduced amount of PA in comparison to those with lower EDSS, thus PwMS of disability levels of EDSS \geq 6.0 are less likely to meet MVPA guidelines and have a greater risk of experiencing CV comorbidities [18]. For example, vascular comorbidities have been significantly correlated to an increased risk of mobility impairment and speed of disability progression [19]. Furthermore, whilst there is evidence that exercise has a multitude of health benefits for PwMS [20–22], few intervention studies have evaluated the effects of PA in persons with greater levels of impairment (e.g. EDSS of 6.0 and above).

Sensorimotor impairments in MS typically impact on the lower limbs, with up to 75% of PwMS experiencing a gait impairment [23]. This can make the use of upper body exercise appealing [24]. Whilst both upper body and lower body exercises may have the potential to elicit cardiovascular adaptations in PwMS, it is important to note that the peripheral adaptation and conditioning of the lower limbs remain vital for PwMS's mobility and contribute to their ability to complete personal and instrumental ADLs [25]. Lower body function is of particular importance in enabling PwMS to remain independent since it supports the completion of personal ADLs such as self-care, transfer and locomotion [26].

Functional Electrical Stimulation (FES) cycling is a suggested lower limb exercise intervention for individuals who have higher levels of impairment [27]. FES cycling can be used where individuals are unable to propel a cycle ergometer independently due to reduced physical function [27]. The intervention applies electrical stimulation to the lower limb muscles, which is appropriately timed to generate cyclical contractions to propel the cycle ergometer [28]. This intervention has reported to benefit other neurological conditions, such as persons with incomplete or complete spinal cord injury (SCI), including increased lower limb skeletal muscle mass, muscular strength, and endurance whilst also improving aerobic capacity, and

1 glucose metabolism [27,29,30]. In PwMS, FES cycling may support higher exercise
2 intensities, enabling greater engagement with the level of MVPA than would be
3 otherwise possible with passive leg cycling; increasing the potential for
4 cardiovascular conditioning [31]. This methodology therefore, may be a feasible
5 option for reducing comorbid CVD risk.
6
7

8
9 Over the last decade, FES cycling has attracted an increased number of
10 investigations due to the potential benefit this intervention has for PwMS, both in
11 terms of supporting their physical functioning, and reducing CVD risk. To date, the
12 evidence remains unclear as to the efficacy of FES cycling to support PwMS in
13 maintaining cardiorespiratory and musculoskeletal health, and preventing the
14 development of further comorbidities. No systematic evaluation has been conducted
15 in this group. Given that FES cycling is a more appropriate intervention for those with
16 higher levels of mobility impairment, the aim of this review is to systematically
17 examine cardiovascular, musculoskeletal and functional outcomes in PwMS with
18 mobility impairment following a FES cycling intervention.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 **2. Methodology**

37 **2.1. Search Strategy**

38
39 This systematic review was conducted was in accordance with the Preferred
40 Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement
41 [32]. A comprehensive literature search was performed in order to examine the effect
42 of FES cycling on cardiovascular, musculoskeletal and functional outcomes in
43 PwMS. Four electronic databases (MEDLINE, Web of Science, CINAHL and PEDro)
44 were searched from their inception to 8th January 2019. Search terms used were as
45 follows: (“Multiple Sclerosis” OR “Progressive MS” OR “Relapsing Remitting MS”)
46 AND (“NMES” OR “FES” OR “ESAC” OR “neuromuscular stimulation” OR “electrical
47 stimulation” OR “stimulation-assisted cycl*” OR “assisted cycl*”). Table 1 provides an
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

example of the search strategy. Filters were applied so that only research articles and articles that were peer-reviewed would be retrieved.

Table 1: Sample Search Strategy

#1	“Multiple Sclerosis” OR “Progressive MS” OR “Relapsing Remitting MS” [all fields]
#2	“NMES” OR “FES” OR “ESAC” OR “neuromuscular stimulation” OR “electrical stimulation” OR “stimulation-assisted cycl*” OR “assisted cycl*” [all fields]
#3	#1 AND #2

NMES = Neuromuscular Electrical Stimulation, FES = Functional Electrical Stimulation, ESAC = Electrical Stimulation-Assisted Cycling.

2.2. Description of the Intervention

FES cycling utilises a commercially available motorised ergometer (e.g. RT300, Restorative Therapies Inc, Baltimore, MD, USA), typically accessed from a seated position [29]. This enables the user to remain on their wheelchair, reducing the requirement for transferring [33]. Stimulation electrodes are placed on the skin, typically above the quadriceps, hamstrings and glutei and a bilateral current is delivered to the muscles providing timed and cyclical stimulation necessary to produce a cycling motion [28,34]. A target cadence is predetermined on the ergometer with suitable software amending the electrical stimulation and ergometer’s resistance based on muscle fibre recruitment and fatigability [30]. Where a participant has leg function, their individual volitional efforts will contribute to attaining the target cadence [33].

2.3. Inclusion Criteria

To be included in this review, the study had to (1) include human participants with definite diagnosis of MS (2) participants had to be aged 18 years and over (3) include participants with an average EDSS 6.0 or above, or an equivalent mobility impairment (4) evaluate FES cycling as an intervention study. Since the number of

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

qualifying studies was anticipated to be small, no restrictions were placed on the type of study included in this review, and all qualifying studies were included regardless of study quality.

2.4. Study Selection

Following searches of the relevant databases, results were imported into bibliographic software (Zotero: V 5.0.60, Fairfax, VA, USA). Subsequently, articles were screened to remove duplicates. Two authors (JS and NS) independently conducted a literature search and screened the title and abstracts of relevant papers to remove studies which clearly did not meet the inclusion criteria. Where it was not clear in the title or abstract if the study was suitable for inclusion, the full text was read. Using the inclusion criteria, both authors independently generated a list of eligible studies.

2.5. Data Extraction

In addition to bibliographic data, the following information was extracted from each article by JS and verified by NS: (i) participant data (ii) intervention protocols (iii) intervention outcomes.

2.6. Study Quality Assessment

Study quality was appraised using four different tools based on study type. The majority of studies were evaluated using the tools designed by the National Heart, Lung and Blood Institute (NHLBI), specifically cohort studies [35] and RCTs [36]. Case studies were evaluated using the tools developed by Murad et al. [37] and retrospective studies using the Newcastle-Ottawa Scale [38].

3. Results

Figure 1 denotes the literature search and screening process undertaken. The initial search found 1162 potential articles supplemented with 1 study from an external source; with 9 of these meeting the inclusion criteria. Of these, 5 were pre-post studies with no control group [33,39–42], two were Randomised Controlled Trials (RCTs) [43,44], one was a retrospective study [45] and one was a case study [46]. Two papers reported different outcomes on the same participant group following the same intervention [43,44]. As a result, there was a total of 9 papers which underwent quality assessment, however these 9 papers describe 8 different interventions. For clarity, the remainder of this review will refer to papers, not interventions.




Figure 1: PRISMA flow diagram of literature search and review process

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 2: Summary of Papers' Participant Data

1
2
3
4
5
6
7

Inclusion criteria of all papers equated to mean EDSS \geq 6.0. 1, demographic data only given for those that completed the

Study [Citation]	Study Design	n	Drop Out	Participant Characteristics		MS Related Measures				Anthropometric Measures		
				Sex	Age (Years)	EDSS Range	Mean EDSS	Disease Duration (Years)	Type of MS	Height (cm)	Body Mass (kg)	Body Mass Index (kg m ²)
Backus <i>et al.</i> [33]	Pre-Post No Control	14	NR	F=7 M=7	55.28 \pm 10.98	NR	NR	15.29 \pm 7.35	PP=2 SP=7 RR=5	NR		
Edwards <i>et al.</i> / Pilutti <i>et al.</i> [43][44] ¹⁵	RCT	CON=5, FES=6	CON=1, FES=2	CON: F=4, FES: F=3 M=1	CON: 48.5 \pm 7.7, FES: 57.3 \pm 6.0	5.5 - 6.5	CON: 6.3 \pm 0.9, FES: 6.3 \pm 0.5	CON: 20.8 \pm 8.5, FES: 22.3 \pm 5.3	CON: P=2 RR=2, FES: P=2 RR=2	CON: 160.5 \pm 9.2, FES: 161.1 \pm 10.4	CON: 85.8 \pm 46.0, FES: 70.6 \pm 19.5	CON: 32.1 \pm 13.9, FES: 27.2 \pm 7.4
Fornusek & Hoang [39]	Pre-Post No Control	8	1	F=8	39 \pm 14	6.5 - 8.5	7.3 \pm 0.7	NR	SP=8	NR		
Emmond <i>et al.</i> [45] ²	Retrospective	CON=10, FES=30	NR	F=27 M=13	54.7 \pm 12	2.5 - 7.5	6.0 \pm 1.4	16.8 \pm 12.7	PP=12 SP=14 RR=14	NR		
Krause <i>et al.</i> [46]	Case Study	1	NR	M=1	46	-	7.5	NR	SP=1	NR		
Ratchford <i>et al.</i> [40]	Pre-Post No Control	5	1	F=2 M=3	50 (median) (range 46 - 60)	6.0 - 6.5	6.5 (median)	13 (median) (range 6 - 21)	PP=2 SP=3	NR		
Reynolds <i>et al.</i> [41] ³	Pre-Post No Control	14	NR	F=1 M=7	54.5 \pm 13.9	NR	NR	16.8 \pm 6.9	PP=2 SP=4 RR=2	NR	NR	24.7 \pm 3.3
Szececi <i>et al.</i> [42] ⁴	Pre-Post No Control	12	4	F=1 M=11	50.9 \pm 6.9	4.0 - 8.0	6.5 \pm 1.1	15.3 \pm 8.2	P=8	NR		

8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

intervention; 2, demographic data not split by control and intervention; 3, demographic data only given for those for those with

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

measurable mVO₂; 4, EDSS unknown for n=1; 5; two papers appear to be same participants and same intervention and have been grouped to prevent double counting; F, female; M, male; PP, Primary Progressive; RR, Relapsing Remitting; SP, Secondary Progressive; P, Progressive; Con, Control Group; FES, FES Cycling Group; NR, Not Reported. Data are mean ± SD unless otherwise stated.

3.1. Demographic Information

The mean participant EDSS in each study was ≥ 6.0 . Of the 9 selected papers, four did not exclusively feature participants with EDSS ≥ 6.0 [42–45]. Two papers did not report participant EDSS however their inclusion criteria approximately equated to that of participants with mobility impairment and EDSS ≥ 6.0 [33,41]. The highest level of impairment reported in participants was EDSS 8.5 [39]. Six papers utilised participants with both progressive and relapsing remitting MS [33,40,41,43–45]. Three exclusively recruited participants with progressive MS [39,42,46]. One study only provided age range therefore from the other 8 papers with extractable data, the mean participant age was 50.77 ± 10.21 years and disease duration 17.14 ± 8.35 years. Two papers, which reported on the same participants reported body height and mass [43,44]. Three papers reported BMI in kg/m^2 [41,43,44].

In three papers, data were only provided for participants who completed the FES cycling intervention [33,41,45]. The same three papers failed to identify the number of participants recruited and drop outs [33,41,45]. Whilst one of the remaining papers was a case study, the other 5 papers reported dropout rates [39,40,42–44]. Two of these papers failed to provide demographic data for participants who withdrew [43,44]. In the four remaining papers a total of 23 out of 31 participants who started the FES cycling protocol completed and 8 dropped out; resulting in a pooled dropout rate of 25.81% [39,40,42,43].

One paper only provided demographic information for those participants where the main outcome, muscle oxygen consumption (mVO_2), was successfully measured [41]. Resting and Peak Heart Rate (HR) was provided in one paper, however these were from baseline assessments and not measured pre and post intervention [39].

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 3: Summary of Papers' Intervention Protocols

Study [Citation]	Study Design	Apparatus	Muscles Stimulated	Target Cadence (rpm)	Stimulation Settings	Session Duration (mins)	Frequency	Study Duration (weeks)	Total Number of Sessions	Total Training Volume (mins)	Continuous Stimulation (C) / Intervals of Stimulation (I)	Progression	Setting	Supervised (Y/N)	Notes
Backus <i>et al.</i> [33]	Pre-Post No Control	RT300	Quadriceps, Hamstrings & Gluteals	35 - 50	PW = 200 μ s; F = 50 Hz	30	3 x a week	4	12	360	C	\uparrow 0.14 Nm Increments (if 3 sessions for 30 mins continuously)	Clinical	Y	If participant was unable to cycling for 30-mins, the cycle entered a passive mode for remainder of session
Edwards <i>et al.</i> / Pilutti <i>et al.</i> [43][44] ¹	RCT	RT300	Quadriceps, Hamstrings & Gluteals	40 - 50	PW = 250 μ s; F = 50 Hz	10 \rightarrow 30	3 x a week	24	72	1800	C	\uparrow 10 min after 4 weeks (until 30 min reached)	Clinical	Y	CON completed on same apparatus.
Fornusek & Hoang [39]	Pre-Post No Control	Motomed Viva 1.5 & Custom Muscle Stimulator	Quadriceps, Hamstrings & Gluteals	10	PW = 300 μ s; F = 35 Hz; Initial SA = 30 mA	40	\approx 1.8 x a week	\approx 10	18	720	C	\uparrow SA at constant rate to reach predetermined level at 20 minutes. Then 20 mins at SA	Clinical	Y	Participants instructed not to push voluntarily during the training.
Hammond <i>et al.</i> [45]	Retrospective	RT300, MotoMed FES Ergometer, Portable Neuromuscular Electrical Stimulation Units 300PV & SWISS Stim among others	NR	NR	NR	\geq 60	\approx 4.4 hours total ABRT a month	\approx 8	\approx 16	\approx 960	NR	NR	Clinical	Y	Part of wider ABRT program. The average prescribed 12-month ABRT consisted of two 3-hour sessions per week administered in two blocks of 4 weeks each.
Krause <i>et al.</i> [46]	Case Study	Constant Current 8-channel Stimulator	Quadriceps, Gluteals & Femoral Biceps	NR	SA: 30 \rightarrow 90 mA	\geq 30	1 x a week	2	2	\approx 60	I	Stimulation increased with tolerance	Clinical	Y	Short breaks of 3-5 mins

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Ratchford <i>et al.</i> [40]	Pre-Post No Control	RT300	Quadriceps, Hamstrings & Gluteals	NR	Initial PD = 250 ± 25% μs; Initial F = 33 - 45 Hz	≥ 60	≈ 3.8 x a week	24	NR	≈ 5472	NR	NR	Home	N	Asked to use at least 3 times per week for at least an hour per session
Reynolds <i>et al.</i> [41]	Pre-Post No Control	RT300	Quadriceps, Hamstrings & Gluteals	40 - 50	NR	30	≈ 3 x a week	4 - 5	12	360	C	↑ 0.14 Nm Increments (if 3 sessions for 30 mins continuously)	Clinical	Y	Stimulation gradually increased to cause cycling at 50 rpm. If participant was unable to cycling for 30-mins, the cycle entered a passive mode for remainder of session
Szecszi <i>et al.</i> [42]	Pre-Post No Control	Theravital Cycle Ergometer & Constant Current 8-channel Stimulator	Quadriceps & Hamstrings	NR	F = 20 Hz; Max SA = 127 mA, Constant PW = 300 μs	12 - 18	3 x a week	2	6	72 - 108	I	NR	Clinical	Y	n=11 received conventional physiotherapy 5 times a week, and outpatient n=1 attended conventional physiotherapy sessions twice a week. Highest cycling resistance was selected that would allow the subject to tolerate well 12–18 min of active ergometric pedalling (with and without stimulation), but at the same time not become too exhausted.

1, two papers appear to be same participants and same intervention and have been grouped to prevent double counting; F, frequency; PW, pulse width; PD, phase duration; SA, stimulation amplitude; NR, not reported; ABRT, Activity Based Restorative Therapy; RT300, Restorative Therapies Inc, Baltimore, MD, USA; Motomed Viva 1.5, Reck Medixintechnik GmbH, Betzenweiller, Germany; Motomed FES Ergometer, Reck Medixintechnik GmbH, Betzenweiller,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Germany; Portable Neuromuscular Electrical Stimulation Units 300PV, Empi, St Paul, MN, USA; SWISS Stim, Valmed, Sion, Swizerland; Constant Current 8-channel Stimulator, Krauth + Timmermann , Germany; Theravital, Medica-Medizintechnik Ltd, Hochdorf, Germany.

3.2. Protocols

Intervention duration ranged between 2 and 24 weeks. Eight papers were completed under supervision in a clinical exercise setting [33,39,41–46] and the remaining paper was undertaken unsupervised at home [40]. Seven papers conducted 2/3 sessions per week for a range of 2 – 24 weeks [33,39–44]. The other two papers were once every week for 2 weeks [46] or completed in two blocks of 4 weeks [45].

In two papers, the protocol was unclear [40,45]. The protocol of five papers was to cycle continuously for a minimum of 10 - 60 minutes utilising FES [33,39,41,43,44]. Of these, the protocol for four papers was to reach a point where a participant could complete 30 minutes of FES cycling at a target cadence of 35 – 50 rpm [33,41,43,44]. Two papers utilised periods of stimulation interspersed with periods of rest [42,46].

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 4: Summary of Papers' Objective Outcome Measures

Study [Citation]	Outcome Measures Pre-Post Intervention	Adverse Events	Type of Adverse Events Reported
Backus <i>et al.</i> [33]	↑ Resistance or Time during FESC ↔ Power during FESC, Lower Limb Strength (Combined MMT of Bilateral HF, KF, KE and AD), Spasticity (MAS), Fatigue (MFIS), Pain (MOS PES), Mental Health (MHI), QOL (MSQLI)	0	-
Edwards <i>et al.</i> / Pilutti <i>et al.</i> [43] [44] ¹	↔ T25FW, MSWS-12, 2MW, TUG, VO _{2peak} , WR _{peak} , KE Strength, KF Strength, Leg FFM, Leg FM, Leg % Fat, Leg BMD, Cognition (SDMT), Fatigue (FSS, MFIS), Pain (SF-MPQ), QOL (MSIS-29)	7 (6 Min, 1 Mod)	Min (n=6): Skin Irritation/Redness n=3, Non-Debilitating Fatigue n=2, Increased Muscle Spasticity n=1 Mod (n=1): Fall Outside of Training
Fornusek & Hoang [39]	↑ Left and Right Thigh Circumference	NR	NR
Hammond <i>et al.</i> [45]	↑ Lower Extremity Motor (ISNCSCI) ↔ Upper Extremity Motor (ISNCSCI), Light Touch (ISNCSCI), Pin Prick (ISNCSCI)	NR	NR
Krause <i>et al.</i> [46]	↓ Spasticity (MAS)	NR	NR
Ratchford <i>et al.</i> [40]	↑ GDNF, IFN γ , IL-8, MIP-1 α , MCP-1 ↔ EDSS, 2MW, T25FW, 9HPT, PASAT, TUG, KE Strength, KF Strength, HE Strength, HF Strength, FD Strength, Lower Limb Sensation, Spasticity (LLSMS), Gait, QOL (SF-36), Mental Health (SCL-90), Other cytokines, chemokines and growth factors	3 (2 Min, 1 Mod)	Min (n=2): Bowel Incontinence n=1, Increased Muscle Spasticity n=1 Mod (n=1): Fall Outside of Training
Reynolds <i>et al.</i> [41]	↑ Resistance or Time during FESC, mVO ₂	0	-
Szecsi <i>et al.</i> [42]	↔ Power during FESC, Smoothness during FESC, 10MWT (ST & LT), KE Strength, KF Strength, Spasticity (MAS, LT) ↓ Spasticity (MAS; ST)	NR	NR

↑, significant increase (p ≤ 0.05); ↔, no significant change; ↓, significant decrease (p ≤ 0.05); 1, two papers appear to be same participants and same intervention and have been grouped to prevent double counting; Min, minor adverse event; Mod, moderate adverse event; FESC, functional electrical

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

stimulation cycling; HE, hip extensor; HF, hip flexor; KF, knee flexor; KE, knee extensor; AD, ankle dorsiflexor; FD, foot dorsiflexor; MMT, manual muscle test; MAS, modified ashworth scale; MFIS, modified fatigue impact scale; SDMT, symbol digit modalities test; SF-MPQ, short-form McGill pain questionnaire; MOS PES, medical outcomes study pain effects scale; MHI, mental health inventory; QOL, quality of life; MSQLI, multiple sclerosis quality of life index; SF-36 = short-form 36; SCL-90, symptom checklist-90; FSS, fatigue severity scale; T25FW, timed 25-foot walk test; 2MW, 2-minute walk; MSWS-12, 12-item multiple sclerosis walking scale; TUG, timed up-and-go; FFM, fat-free mass; FM, fat mass; BMD, bone mineral density; MSIS-29, 29-item multiple sclerosis impact scale; ISNCSCI, international standards for neurological classification of spinal cord injury; 9HPT, 9-hole peg test; PASAT, paced auditory serial addition test; LLSMS, lower limb spasticity measurement system; GDNF, glial cell-derived neurotrophic factor; IFN γ , interferongamma; IL-8, interleukin-8; MIP- α , macrophage inflammatory protein-1 alpha; MCP-1, monocyte chemotactic protein-1; 10MWT, 10m Walk Test; ST, Short-Term; LT, Long-Term.

3.3. Cardiorespiratory Performance

One paper investigated $m\dot{V}O_2$ and reported no improvement following a FES cycling intervention [41]. One paper measured peak aerobic capacity (VO_{2peak}) across control and intervention groups and measured no change [43]. Peak work rate (WR_{peak}) was measured in one paper, with no improvement following the intervention [43]. Two papers measured power generation during FES cycling across the duration of the intervention, reporting no change [33,42]. In two papers, where participants could cycle continuously for 30 minutes, the resistance at which they could cycle significantly increased [33,41]. Conversely, in the same two papers, where participants were unable to cycle continuously for 30 minutes, active cycling time significantly increased [33,41].

3.4. Functional Performance

Walking performance was measured in three papers in a variety of tests; 2-minute walk test (2MW) [40,43], timed 25-foot walk test (T25FW) [40,43], 10m Walk Test (10MWT) [42] and 12-item MS Walking Scale (MSWS-12) [43]. All three papers reported insignificant changes [40,42,43]. Timed Up-and-Go (TUG) performance was measured in two papers; with no change post FES cycling [40,43].

3.5. Musculoskeletal Outcomes

Lower body strength was commonly measured in the Knee Extensors (KE), Knee Flexors (KF), Hip Extensors, Hip Flexors and/or Dorsiflexors or in combined tests [33,40,42,43]. Three papers found no improvement in either KE or KF strength [40,42,43]. Combined strength testing of the Hip Flexors, KE, KF & Dorsiflexors did not change [33]. One study, that observed a significant increase in thigh volume failed to measure changes in muscle mass or fat free mass in order to ascertain the cause of such increase [39].

The most frequently measured parameter was spasticity [33,39,40,42,46]. Three papers utilised the Modified Ashworth Scale (MAS) [33,42,46]. One study utilised the

1 Lower Limb Spasticity Measurement System (LLSMS) [40]. One study used self-
2 reporting [39]. Three papers reported a reduction in spasticity post FES cycling; two
3 papers described significant improvements in spasticity directly post FES cycling
4 [42,46] and one paper described self-evaluated measures on an unspecified time
5 frame [39]. Four papers reported no longer term improvements when measures were
6 taken on different days [33,40,42,46].
7
8
9

10 **3.6. Psychological Outcomes**

11 Two papers evaluated mental health finding no change utilising the Mental Health
12 Inventory (MHI) and Symptom Checklist-90 accordingly [33,40]. Quality of Life was
13 measured in three papers with no significant change post FES cycling [33,40,44].
14
15
16
17
18
19
20
21

22 **3.7. Adverse Events**

23 Four papers did not explicitly report any information regarding adverse events
24 [39,42,45,46]. Of the five remaining papers, a total of 36 participants reported 10
25 adverse events; none of which were described as serious [33,40,41,43,44]. Only two
26 papers specifically discuss MS-related adverse events and in both cases, none were
27 reported [33,41]. Two papers reported 8 minor events which included skin irritation,
28 increased spasticity, bowel dysfunction and fatigue [40,43]. Two papers both
29 reported a moderate adverse event which caused a participant to drop out; both of
30 which were falls noted by researchers as unrelated to the intervention [40,43].
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Study [Citation]	Research question clear?	Participant eligibility criteria clear?	Participants representative of clinical population of interest?	Were all eligible participants enrolled?	Was sample size sufficiently large to provide confidence in the findings?	Was the intervention clearly described and delivered consistently?	Outcome measures prespecified, clear, valid and reliable? Assessed consistently?	Blinded assessment of outcomes?	Loss to follow-up after baseline ≤20%	Did the statistical method examine changes pre and post intervention? p values provided?	Outcome measures taken multiple times pre and post intervention?
Backus <i>et al.</i> [33]	Y	Y	Y	Y	UC	Y	Y	N	NR	Y	N
Fornusek & Hoang [39]	Y	Y	Y	Y	UC	Y	N	N	Y	N	N
Ratchford <i>et al.</i> [40]	Y	Y	Y	Y	N	Y	Y	N	Y	N	N
Reynolds <i>et al.</i> [41]	Y	Y	Y	Y	UC	Y	Y	N	NR	Y	N
Szecs <i>et al.</i> [42]	Y	Y	Y	Y	UC	Y	Y	N	N	Y	N

Table 5: NHLBI Quality Assessment Tool for Before-After (Pre-Post) Studies With No Control Group

Y, yes; N, no; UC, unclear; NR, not reported.

Study [Citation]	Domain								
	Selection	Ascertainment		Causality				Reporting	
	Patient represent whole experience of the investigator or is the selection method unclear to the extent that other patients with similar presentation may not have been reported?	Exposure adequately ascertained?	Outcome adequately ascertained?	Other alternative causes that may explain the observation ruled out?	Challenge/rechallenge phenomenon?	Dose-response effect?	Follow-up long enough for outcomes to occur?	Case described with sufficient details to allow other investigators to replicate the research or to allow practitioners make inferences related to their own practice?	
Krause <i>et al.</i> [46]	UC	Y	Y	N	N	N	Y	Y	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 6: Quality Assessment of Case Reports and Case Series

Study [Citation]	Study described as RCT?	Method of randomisation adequate?	Treatment allocation concealed?	Study participants and providers blinded to treatment group assignment?	Outcome assessors blinded to participants' group assignments?	Groups similar at baseline on important characteristics that could affect outcomes?	Drop out rate at endpoint $\leq 20\%$ or lower of number allocated to treatment?	Differential drop-out rate at endpoint $\leq 15\%$	High adherence to intervention protocols for each treatment group?	Were other interventions avoided or similar in the groups?	Were outcomes assessed using valid and reliable measures, implemented consistently across all participants?	Sample size sufficiently large to detect difference in main outcome between groups with $\geq 80\%$ power?	Outcomes reported or subgroups analysed prespecified?	All randomised participants analysed in group to which they were originally assigned?
------------------	-------------------------	-----------------------------------	---------------------------------	---	---	---	--	--	--	--	---	--	---	---

Y, yes; N, no; UC, unclear.

Table 7: NHLBI Quality Assessment for Controlled Intervention Studies

1															
2															
3															
4															
5															
6															
7	Edwards <i>et al.</i>	Y	Y	Y	N	Y	Y	N	Y	Y	NR	Y	N	Y	N
8	/ Pitti <i>et al.</i>														
9	[43][44]														
10															

Y, yes; N, no; NR, not reported; 1, two papers appear to be same participants and same intervention and have been grouped to prevent double counting.

Table 8: Newcastle-Ottawa Quality Assessment Scale for Case Control Studies

Study [Citation]	Domain							
	Selection				Comparability	Outcome		
	Case Definition Adequate?	Representativeness of cases	Selection of controls	Definition of controls	Comparability of cases and controls on basis of design or analysis	Ascertainment of exposure	Same ascertainment for cases and controls	Non-response rate
Hammond <i>et al.</i> [45]	★		★			★	★	

★, one star.

3.8. Study Quality

The study quality assessment tools indicated that papers consistently had unclear or insufficient sample sizes to provide confidence in the findings. The largest sample size was that of a retrospective study, which contained 40 participants [45]. Of the 8 other papers, sample size ranged from 1 to 14 [33,39–44,46]. Across all nine papers, 82 participants were reported to complete a FES cycling intervention, but outcome data was only provided for 76 [33,39–46]. Only two papers had a blinded assessment of outcome measures [43,44]. Across the 7 papers with cohort study designs [33,39–44], only 2 reported a dropout rate $\leq 20\%$ [39,40]. None of the papers included in this review recorded outcome measures multiple times following a FES cycling intervention [33,39–46].

4. Discussion

The aim of this systematic review was to conduct a comprehensive literature search examining the effect of FES cycle training on cardiovascular, musculoskeletal and functional outcomes in PwMS and EDSS ≥ 6.0 . The heterogeneity in outcome measures across the nine papers prevented a meta-analysis. The low quality of the literature base precludes any definitive conclusions regarding the efficacy of FES cycle training in improving cardiovascular health in PwMS and higher EDSS scores. In the present review, one of the main findings is that FES cycle training appears to be well tolerated in PwMS with mobility impairment, with no serious adverse events.

4.1. Cardiorespiratory Performance

Aerobic capacity is a strong indicator of cardiovascular fitness and associated CVD risk in PwMS [7]. CVD is of particular risk for PwMS, with papers demonstrating that PwMS are more likely to have CVD in comparison to healthy controls [5,47]. Although definitive data is lacking, it is plausible that those with the greatest level of mobility impairment are subject to an increased risk of CVD, with a significant correlation between disease progression and aerobic capacity [7,14]. Whilst aerobic training has been demonstrated to reduce this CVD in PwMS [48]; the majority of this work has been in those with EDSS < 6.0 , whereas those with higher mobility

1 impairment (e.g. EDSS \geq 6.0) have been poorly researched in the literature [48].
2 FES cycling has the potential to increase the dose of exercise attainable in PwMS
3 with higher mobility impairment, and could therefore increase aerobic capacity and
4 PA [31,49]. However, despite this potential, from the evidence of this review, the
5 effectiveness of FES cycling in improving aerobic capacity is equivocal. Only two
6 papers recorded valid objective measures of aerobic capacity [41,43]. One paper
7 found a significant increase in peripheral oxygen consumption ($m\dot{V}O_2$) following 360
8 minutes of FES cycle training across 4 weeks while the other study reported trends
9 for improvement in VO_{2peak} that fell short of statistical significance [38,42]. In both
10 cases, the samples were small ($n \leq 8$) and the studies were underpowered, making it
11 difficult to draw definitive conclusions.
12
13
14
15
16
17
18
19
20

21 Walking tests are associated with aerobic capacity in PwMS [12]. In the present
22 review, walking performance was the most frequently utilised functional test
23 [40,42,43] however no papers reported any improvements. This apparent limited
24 effectiveness may be due to the lack of specificity since walking performance is also
25 reliant on balance and lower limb strength asymmetries [12]. Moreover, whether
26 different doses of exercises would be more effective (e.g. longer duration or higher
27 intensity) remain to be determined. Indeed, the high level of variability within the FES
28 cycling interventions makes it difficult to attribute any changes to a specific protocol.
29 While four of the nine papers had similar protocols [33,41,43,44], only two had
30 matched training volumes and outcome measures in both papers had a high level of
31 variability [33,39].
32
33
34
35
36
37
38
39
40
41
42
43
44

45 **4.2. Cardiovascular Risk Factors**

46
47 Obesity, typically measured utilising BMI, is a well-accepted and independent risk
48 factor for CVD [50]. Given the increased risk of CVD in PwMS compared to the
49 general population, it is surprising that only two papers provided BMI data [41,43].
50 One paper gave baseline measures for BMI [41]. The other paper provided more
51 nuanced assessment of fat free mass, fat mass and bone density (measured utilising
52 a bone densitometer) and reported no change following FES cycle training [43]. The
53 overall poor reporting of BMI and small sample size in Edwards et al. [43] makes it
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

difficult to assess the role of FES cycle training in preventing obesity as a CVD risk factor.

However, the accuracy of standard BMI thresholds for persons with lower limb impairment have been questioned since BMI does not distinguish between muscle and fat compartments [51]. Consequently, in persons with reduced lower limb muscle tone and bone density, BMI thresholds designed for able bodied persons may underestimate the risk of increased body fat [51]. Notably, in this regard FES cycling has been reported to improve body composition including increase in lean tissue in persons with SCI [52]. However, the potential of FES cycling to produce similar effects in PwMS is yet to be investigated.

4.3. Spasticity

Spasticity is a common and debilitating symptom for persons with MS [53,54]. In particular, this is important for PwMS since disease progression and duration are both strongly correlated with spasticity and reductions in mobility [54,55]. Alongside a reduction in mobility and associated independence, spasticity can also be a direct source of MS-related pain [56]. FES cycling has been suggested as a possible support mechanism for spasticity since it is associated with a reduction in spastic muscle tone in persons with SCI [58] but the degree to which this is the case with PwMS remains to be determined.

Spasticity was the most commonly recorded measure, and FES cycle training appears to acutely improve symptoms of spasticity but this does not appear to translate into medium term effects (defined as approximately 48 hours after training) [42,46]. No papers evaluated longer term effects of FES cycling and thus the effect of FES cycle training in reducing spasticity > 48 hours remains unclear. The MAS was the most frequently utilised measurement within this review and is commonly used to measure spasticity in persons with MS [55]. That being said, a number of limitations are reported with the MAS related to inter-rater reliability, sensitivity to change and insufficient guidelines regarding its use [52,54]. Future studies should look to use more robust measures of spasticity with less subjectivity.

4.4. Lower Limb Muscular Strength

Lower Limb Muscular Strength is correlated to walking performance in PwMS and is important in enabling PwMS to complete personal and instrumental ADLs [26,57]. Clearly, one aim of FES cycling is to stimulate the musculature of the lower limbs thus aiming to increase strength, reduce the rate of decline and preserve function in the lower body; with the potential to support PwMS's ability to maintain ADLs. Moreover when this lower limb function is lost, this in turn translates into greater loads being placed on the upper body and a higher risk of chronic upper body injury [58,59]. Four papers assessed this outcome, however no improvements in lower body muscular strength following FES cycle training were found within the present review [33,40,42,43].

Clearly, cycling is generally considered to be aerobic in nature and may be considered to produce modest increases in muscular strength. Indeed, to elicit skeletal muscle hypertrophy in healthy populations using aerobic exercise, the optimum exercise intensity is suggested as a minimum of 70% HR reserve (HRR), 4 times a week for 30 minutes [60]. Given that none of the papers included in this review had sufficient exercise volume to equate to this, nor was %HRR or %VO_{2peak} set as a target within the interventions, it is perhaps not surprising that no changes in strength were noted. Moreover, FES cycling can be considered as a dynamic training modality with moderate speeds of muscle contraction. However, in all cases, strength was assessed isometrically using semi-quantitative [33,42], static [45] or isokinetic [43] methods. It is well established that changes in strength are specific to the speed and type of contraction used in training, and outcome measures should reflect the training mode [61]. Indeed, strong correlations only existed between isometric and dynamic strength using large forces, or explosive power as anticipated [62], which was not the case in the interventions used in the papers.

Consequently, the conclusion that FES cycling does not improve strength in PwMS with EDSS \geq 6.0 should be viewed with caution, and must be re-evaluated with more appropriate protocols, given the mismatch between training stimulus and outcome assessment. Evidence has shown that PwMS and mobility impairment can reach

1 higher %HR_{peak} during an acute bout of FES cycling in comparison to passive leg
2 cycling (76.4%HR_{peak} vs 55.5%HR_{peak}) [31]. This supports the theory that FES cycling
3 protocols have the potential to provide increases in strength. A further limitation is
4 that of the papers in this review, only two interventions were longer than 10 weeks
5 and in both cases, sample sizes were too small to make meaningful interpretations
6 (n=4 completed in both cases) [40,43,44]. Another consideration for those papers
7 that measured muscular strength, is that the majority had no control group. As
8 disease progression is correlated to reductions in lower limb muscular strength,
9 future research should look to determine if maintenance of muscular strength is
10 clinically meaningful over time in comparison to controlled counterparts [12].
11
12
13
14
15
16
17
18
19
20

21 **4.5. Adverse Events & Adherence**

22
23 Accurate reporting of adverse events is particularly important in this group since
24 there are few intervention papers evaluating the benefits of PA in persons with EDSS
25 ≥ 6.0 [20–22]. In general, previous studies have indicated exercise to be safe in
26 PwMS, with one systematic review of RCT's reporting no increased risk of relapse
27 [63]. However, a notable limitation is that, in that review, only one of the papers
28 included participants with a mean EDSS ≥ 6.0 and none included participants with an
29 EDSS > 6.5 [63]. One systematic review has reported on exercise interventions for
30 PwMS and EDSS ≥ 6.0 but did not come to any meaningful conclusions regarding
31 exercise safety, in part due to the small number of research papers evaluating this
32 population [64]. This present review extends these findings, by identifying consistent,
33 if limited evidence that FES cycle training in PwMS who have an EDSS ≥ 6.0
34 appears to be well tolerated with no serious adverse events. Moreover, while there
35 are clear differences in aetiology, this finding is in broad agreement with substantial
36 evidence regarding the reported benefits of FES cycling and safety in persons with
37 SCI [65].
38
39
40
41
42
43
44
45
46
47
48
49
50

51
52
53 Whilst encouraging, it is important to note that reporting of adverse events was
54 generally poor, making more detailed recommendations in PwMS and higher EDSS
55 scores difficult. Moreover, PwMS and EDSS ≥ 6.0 are relatively poorly represented
56 in the MS literature regarding exercise interventions, with little information in regards
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

to adherence to exercise interventions, and potential barriers to participation they experience. Future FES cycling studies should seek to explicitly provide adverse event data in this population.

This review also found poor reporting of participant recruitment and dropout rates thus impacting on the conclusions which can be drawn regarding attrition. By only reporting the outcomes of those completing an intervention, investigators risk attrition bias which, hampers the understanding of exercise adherence and the capacity of this population to sustain FES cycling at prescribed training volumes [66]. Understanding exercise adherence and how to increase participation in persons with MS is an important area for future research [2].

4.6. Quality of the Literature

Nine papers of varying study design were considered in this review. Most papers had small sample sizes that lacked justification, and therefore had underpowered statistical analysis. For example, the sample sizes across all the pre-post cohort studies were relatively small. Moreover, two papers attempted to overcome sample size limitations by calculating effect sizes for all insignificant outcomes [43,44]. While this is understandable, it is important that insignificant improvements aren't assumed to be type 2 errors, as underpowered studies may also artificially inflate the effect size [67]. Studies must seek to increase their sample sizes or provide statistical justification for their sample size use if any meaningful conclusions regarding the effect of FES cycling in persons with MS are to be assessed. The only study to have sufficient sample size for statistical power was the retrospective paper by Hammond et al. [45]. However, in this case, participation allocation into either FES cycling or control groups was decided for clinical reasons, suggesting that finding may be affected by allocation bias [68].

Of concern is the preponderance of subjective outcome measures in certain papers [39]. This study reported significant improvements in several self-evaluated outcomes including increases in circulation, strength, balance and muscle mass and reductions in pain, cramp and spasticity (self-reported measures with no statistical

1 testing were not included in Table 4). This is of concern given the use of an
2 intervention group and no control; with clear risk of response bias and the potential
3 for treatment effect [69]. The study provided resting and peak HR, however, this was
4 poorly reported with resting and HR_{MAX} values only assessed pre intervention,
5 making interpretation difficult [39].
6
7
8
9

10
11
12 Whilst the present review affirms the requirement for evaluating cardiorespiratory
13 performance and FES cycle training in PwMS and EDSS ≥ 6.0 , the lack of consistent
14 measures of cardiorespiratory performance or other measures of CVD risk, mean it
15 is difficult to draw conclusions regarding the effect on their cardiovascular health and
16 CVD risk. Future research should accurately monitor cardiorespiratory performance
17 and CVD risk factors before and after FES cycle training in PwMS and EDSS ≥ 6.0 .
18
19
20
21
22
23
24

25
26 Two interventions would not be replicable based on the information provided within
27 the papers reviewed [40,45]. If the quality of evidence regarding FES cycling in
28 PwMS is to improve, there is a clear requirement for statistically justifiable sample
29 sizes and a consistency in intervention protocols/testing parameters to enable a
30 future quantitative analysis. None of the papers included in this review had a follow
31 up and so it remains unclear if there are any long lasting changes in outcome
32 measures following a FES cycling intervention. In particular, this is important for
33 PwMS based on the degenerative nature of the condition; where no change over
34 time may represent a net clinical benefit.
35
36
37
38
39
40
41
42

43 The use of functional tests was typically favoured in the present review in place of
44 direct measures (Table 4). Whilst maintaining and/or improving function is of clear
45 priority for PwMS when participating in exercise; it is important to note that the
46 underlying mechanisms for conditioning and preservation of this function in PwMS
47 and FES cycling are not understood at present. As such, isolating the underlying
48 reasons for changes in functional tests and hence, the use of direct measures
49 remains of important when evaluating FES cycling in PwMS.
50
51
52
53
54
55

56 Most FES Cycling research has been in persons with complete SCI and the transfer
57 of this exercise modality to PwMS is justifiable. However, future research must
58 appreciate that PwMS will require different protocols which will need to be fully
59
60
61
62
63
64
65

1 reported. In particular, PwMS may still have some lower limb function making it more
2 difficult to differentiate between the work provided by the individual (i.e. via central
3 command) versus that provided by the stimulation. It would be beneficial if
4 researchers clearly stated if participants were instructed and/or encouraged to cycle
5 volitionally, and to what level/effort. For example, one paper in the present review
6 instructed participants not to cycle volitionally, as the aim of their research was to
7 isolate the effect of the electrical stimulation [39]. Volitional effort being encouraged
8 or discouraged is not clearly reported across all the papers within this review. Where
9 participants are asked to actively cycle, the variance in stimulation and WR across
10 the session could provide insight regarding participant fatigability.
11
12
13
14
15
16
17
18
19
20
21

22 **5. Conclusion**

23
24
25
26 The current systematic review suggest that FES cycle training appears to be well
27 tolerated in PwMS with mobility impairment. Findings suggest that FES cycle training
28 may reduce CVD risk in some persons alongside trends suggesting reductions in
29 spasticity post training. However, the low quality of the literature base precludes any
30 definitive conclusions regarding the efficacy of FES cycle training in improving
31 cardiovascular, musculoskeletal and functional outcomes in PwMS and higher EDSS
32 scores. Future research should examine the use of FES cycle training in PwMS and
33 mobility impairment using larger sample sizes, with correct statistical power,
34 consistent cycle protocols and utilising direct objective measurable outcomes.
35
36
37
38
39
40
41
42
43
44

45 **Funding**

46
47
48 JS receives funding for a studentship from the Chief Scientific Office (CSO) for
49 Scotland (MMPP_02).
50
51

52 **Declaration of Conflicting Interests**

53
54
55 This work was part funded by the Chief Scientific Office (CSO) for Scotland, although
56 they had no say regarding the aims, analysis, nor interpretation of data. No authors
57 have any other conflicts of interest to declare.
58
59
60
61
62
63
64
65

References

1. Kierkegaard M, Lundberg IE, Olsson T, Johansson S, Ygberg S, Opava C, et al. High-intensity resistance training in multiple sclerosis - An exploratory study of effects on immune markers in blood and cerebrospinal fluid, and on mood, fatigue, health-related quality of life, muscle strength, walking and cognition. *J Neurol Sci.* 2016;362:251–7.
2. Motl RW, Sandroff BM, Pilutti LA, Klaren RE, Baynard T, Fernhall B. Physical activity, sedentary behavior, and aerobic capacity in persons with multiple sclerosis. *J Neurol Sci.* 2017;372:342–6.
3. Motl RW. Ambulation and Multiple Sclerosis. *Physical Medicine and Rehabilitation Clinics of North America.* 2013;24:325–36.
4. Klaren RE, Motl RW, Dlugonski D, Sandroff BM, Pilutti LA. Objectively quantified physical activity in persons with multiple sclerosis. *Arch Phys Med Rehabil.* 2013;94:2342–8.
5. Wens I, Eijnde BO, Hansen D. Muscular, cardiac, ventilatory and metabolic dysfunction in patients with multiple sclerosis: Implications for screening, clinical care and endurance and resistance exercise therapy, a scoping review. *J Neurol Sci.* 2016;367:107–21.
6. Stroud N, Minahan C, Sabapathy S. The perceived benefits and barriers to exercise participation in persons with multiple sclerosis. *Disabil Rehabil.* 2009;31:2216–22.
7. Heine M, Wens I, Langeskov-Christensen M, Verschuren O, Eijnde BO, Kwakkel G, et al. Cardiopulmonary fitness is related to disease severity in multiple sclerosis. *Mult Scler.* 2016;22:231–8.
8. Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Cutter G, et al. A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. *Multiple Sclerosis Journal.* 2015;21:318–31.
9. Jadidi E, Mohammadi M, Moradi T. High risk of cardiovascular diseases after diagnosis of multiple sclerosis. *Multiple Sclerosis Journal.* 2013;19:1336–40.
10. Lalmohamed A, Bazelier MT, Van Staa TP, Uitdehaag BMJ, Leufkens HGM, De Boer A, et al. Causes of death in patients with multiple sclerosis and matched referent subjects: a population-based cohort study: Causes of death in patients with MS. *European Journal of Neurology.* 2012;19:1007–14.
11. Jick SS, Li L, Falcone GJ, Vassilev ZP, Wallander M-A. Mortality of patients with multiple sclerosis: a cohort study in UK primary care. *Journal of Neurology.* 2014;261:1508–17.
12. Sandroff BM, Sosnoff JJ, Motl RW. Physical fitness, walking performance, and gait in multiple sclerosis. *J Neurol Sci.* 2013;328:70–6.
13. Sandroff BM, Pilutti LA, Motl RW. Does the six-minute walk test measure walking performance or physical fitness in persons with multiple sclerosis? *NeuroRehabilitation.* 2015;37:149–55.

- 1 14. Pilutti LA, Sandroff BM, Klaren RE, Learmonth YC, Platta ME, Hubbard EA, et al. Physical Fitness
2 Assessment Across the Disability Spectrum in Persons With Multiple Sclerosis: A Comparison of
3 Testing Modalities. *J Neurol Phys Ther.* 2015;39:241–9.
- 4 15. Motl RW, Learmonth YC. Neurological disability and its association with walking impairment in
5 multiple sclerosis: brief review. *Neurodegener Dis Manag.* 2014;4:491–500.
- 6 16. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale
7 (EDSS). *Neurology.* 1983;33:1444–1444.
- 8 17. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. *Brain.*
9 2006;129:606–16.
- 10 18. Beckerman H, de Groot V, Scholten MA, Kempen JCE, Lankhorst GJ. Physical activity behavior of
11 people with multiple sclerosis: understanding how they can become more physically active. *Phys*
12 *Ther.* 2010;90:1001–13.
- 13 19. Marrie RA, Rudick R, Horwitz R, Cutter G, Tyry T, Campagnolo D, et al. Vascular comorbidity is
14 associated with more rapid disability progression in multiple sclerosis. *Neurology.* 2010;74:1041–7.
- 15 20. Latimer-Cheung AE, Pilutti LA, Hicks AL, Martin Ginis KA, Fenuta AM, MacKibbon KA, et al. Effects
16 of Exercise Training on Fitness, Mobility, Fatigue, and Health-Related Quality of Life Among Adults
17 With Multiple Sclerosis: A Systematic Review to Inform Guideline Development. *Archives of Physical*
18 *Medicine and Rehabilitation.* 2013;94:1800-1828.e3.
- 19 21. Platta ME, Ensari I, Motl RW, Pilutti LA. Effect of Exercise Training on Fitness in Multiple Sclerosis:
20 A Meta-Analysis. *Arch Phys Med Rehabil.* 2016;97:1564–72.
- 21 22. Ewanchuk BW, Gharagozloo M, Peelen E, Pilutti LA. Exploring the role of physical activity and
22 exercise for managing vascular comorbidities in people with multiple sclerosis: A scoping review.
23 *Multiple Sclerosis and Related Disorders.* 2018;26:19–32.
- 24 23. Lee Y, Chen K, Ren Y, Son J, Cohen BA, Sliwa JA, et al. Robot-guided ankle sensorimotor
25 rehabilitation of patients with multiple sclerosis. *Multiple Sclerosis and Related Disorders.*
26 2017;11:65–70.
- 27 24. Skjerbæk A, Næsby M, Lützen K, Møller A, Jensen E, Lamers I, et al. Endurance training is feasible
28 in severely disabled patients with progressive multiple sclerosis. *Multiple Sclerosis Journal.*
29 2014;20:627–30.
- 30 25. Paltamaa J, Sjogren T, Peurala SH, Heinonen A. Effects of physiotherapy interventions on balance
31 in multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials. *J Rehabil*
32 *Med.* 2012;44:811–23.
- 33 26. Månsson E, Lexell J. Performance of activities of daily living in multiple sclerosis. *Disability and*
34 *Rehabilitation.* 2004;26:576–85.
- 35 27. Davis GM, Hamzaid NA, Fornusek C. Cardiorespiratory, Metabolic, and Biomechanical Responses
36 During Functional Electrical Stimulation Leg Exercise: Health and Fitness Benefits. *Artificial Organs.*
37 2008;32:625–9.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
28. Duffell LD, Donaldson N de N, Perkins TA, Rushton DN, Hunt KJ, Kakebeeke TH, et al. Long-term intensive electrically stimulated cycling by spinal cord-injured people: Effect on muscle properties and their relation to power output. *Muscle & Nerve*. 2008;38:1304–11.
 29. Thrasher T, Ward J, Fisher S. Strength and endurance adaptations to functional electrical stimulation leg cycle ergometry in spinal cord injury. *NeuroRehabilitation*. 2013;133–138.
 30. Griffin L, Decker MJ, Hwang JY, Wang B, Kitchen K, Ding Z, et al. Functional electrical stimulation cycling improves body composition, metabolic and neural factors in persons with spinal cord injury. *Journal of Electromyography and Kinesiology*. 2009;19:614–22.
 31. Edwards T, Motl RW, Pilutti LA. Cardiorespiratory demand of acute voluntary cycling with functional electrical stimulation in individuals with multiple sclerosis with severe mobility impairment. *Applied Physiology, Nutrition, and Metabolism*. 2018;43:71–6.
 32. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Medicine*. 2009;6:6.
 33. Backus D, Burdett B, Hawkins L, Manella C, McCully KK, Sweatman M. Outcomes After Functional Electrical Stimulation Cycle Training in Individuals with Multiple Sclerosis Who Are Nonambulatory. *International Journal of MS Care*. 2017;19:113–21.
 34. Fornusek C, Davis GM. Cardiovascular and Metabolic Responses During Functional Electric Stimulation Cycling at Different Cadences. *Archives of Physical Medicine and Rehabilitation*. 2008;89:719–25.
 35. Quality Assessment for Before-After (Pre-Post) Studies With No Control Group [Internet]. National Heart, Lung and Blood Institute (NHLBI). 2014 [cited 2019 Mar 13]. Available from: <https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools>
 36. Quality Assessment of Controlled Intervention Studies [Internet]. National Heart, Lung and Blood Institute (NHLBI). 2014 [cited 2019 Mar 13]. Available from: <https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools>
 37. Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. *BMJ Evidence-Based Medicine*. 2018;23:60–3.
 38. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non Randomised Studies in Meta-Analyses [Internet]. 2019 [cited 2019 Mar 13]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
 39. Fornusek C, Hoang P. Neuromuscular electrical stimulation cycling exercise for persons with advanced multiple sclerosis. *Journal of Rehabilitation Medicine*. 2014;46:698–702.
 40. Ratchford JN, Wendy S, R HE, Gregory RJ, Robert R, Pingting N, et al. A pilot study of functional electrical stimulation cycling in progressive multiple sclerosis. *Neurorehabilitation*. 2010;121–128.
 41. Reynolds MA, McCully K, Burdett B, Manella C, Hawkins L, Backus D. Pilot Study: Evaluation of the Effect of Functional Electrical Stimulation Cycling on Muscle Metabolism in Nonambulatory People With Multiple Sclerosis. *Archives of Physical Medicine and Rehabilitation*. 2015;96:627–32.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
42. Szecsi J, Schlick C, Schiller M, Pöllmann W, Koenig N, Straube A. Functional electrical stimulation-assisted cycling of patients with multiple sclerosis: Biomechanical and functional outcome – A pilot study. *Journal of Rehabilitation Medicine*. 2009;41:674–80.
43. Edwards T, Motl RW, Sebastião E, Pilutti LA. Pilot randomized controlled trial of functional electrical stimulation cycling exercise in people with multiple sclerosis with mobility disability. *Multiple Sclerosis and Related Disorders*. 2018;26:103–11.
44. Pilutti LA, Edwards T, Motl RW, Sebastião E. Functional Electrical Stimulation Cycling Exercise in Persons with Multiple Sclerosis: Secondary Effects on Cognition, Symptoms, and Quality of Life. *International Journal of MS Care [Internet]*. 2018 [cited 2019 Mar 6]; Available from: <http://ijmsc.org/doi/10.7224/1537-2073.2018-048>
45. Hammond ER, Recio AC, Sadowsky CL, Becker D. Functional electrical stimulation as a component of activity-based restorative therapy may preserve function in persons with multiple sclerosis. *The Journal of Spinal Cord Medicine*. 2015;38:68–75.
46. Krause P, Szecsi J, Straube A. FES cycling reduces spastic muscle tone in a patient with multiple sclerosis. :3.
47. Mincu RI, Magda SL, Mihaila S, Florescu M, Mihalcea DJ, Velcea A, et al. Impaired Cardiac Function in Patients with Multiple Sclerosis by Comparison with Normal Subjects. *Scientific Reports*. 2018;8:3300.
48. Howe J-AA, Gomperts MA. Aerobic Testing and Training for Persons with Multiple Sclerosis: A Review with Clinical Recommendations. *Physiotherapy Canada*. 58:12.
49. Dolbow DR, Gorgey AS, Ketchum JM, Gater DR. Home-Based Functional Electrical Stimulation Cycling Enhances Quality of Life in Individuals with Spinal Cord Injury. *Top Spinal Cord Inj Rehabil*. 2013;19:324–9.
50. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss: An Update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease From the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. *Circulation*. 2006;113:898–918.
51. Bandini L, Danielson M, Esposito LE, Foley JT, Fox MH, Frey GC, et al. Obesity in children with developmental and/or physical disabilities. *Disability and Health Journal*. 2015;8:309–16.
52. Frotzler A, Coupaud S, Perret C, Kakebeeke TH, Hunt KJ, Donaldson N de N, et al. High-volume FES-cycling partially reverses bone loss in people with chronic spinal cord injury. *Bone*. 2008;43:169–76.
53. Haas J. Pathophysiology, assessment and management of multiple sclerosis spasticity: an update. *Expert Review of Neurotherapeutics*. 2011;11:3–8.
54. Pozzilli C. Overview of MS Spasticity. *European Neurology*. 2014;71:1–3.
55. Tintoré M. Advances in the management of multiple sclerosis symptoms: pathophysiology and assessment of spasticity in multiple sclerosis. *Neurodegenerative Disease Management*. 2015;5:15–7.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
56. Truini A, Barbanti P, Pozzilli C, Cruccu G. A mechanism-based classification of pain in multiple sclerosis. *Journal of Neurology*. 2013;260:351–67.
57. Kjølhede T, Vissing K, Dalgas U. Multiple sclerosis and progressive resistance training: a systematic review. *Multiple Sclerosis Journal*. 2012;18:1215–28.
58. Jain NB, Higgins LD, Katz JN, Garshick E. Association of Shoulder Pain With the Use of Mobility Devices in Persons With Chronic Spinal Cord Injury. *PM&R*. 2010;2:896–900.
59. Haubert LL, Gutierrez DD, Newsam CJ, Gronley JK, Mulroy SJ, Perry J. A Comparison of Shoulder Joint Forces During Ambulation With Crutches Versus a Walker in Persons With Incomplete Spinal Cord Injury. *Archives of Physical Medicine and Rehabilitation*. 2006;87:63–70.
60. Konopka AR, Harber MP. Skeletal Muscle Hypertrophy after Aerobic Exercise Training. *Exerc Sport Sci Rev*. 2014;42:53–61.
61. Baker D, Wilson G, Carlyon B. Generality versus specificity: a comparison of dynamic and isometric measures of strength and speed-strength. *Europ J Appl Physiol*. 1994;68:350–5.
62. Juneja H, Verma SK, Khanna GL. Isometric Strength and Its Relationship to Dynamic Performance: A Systematic Review. *Journal of Exercise Science and Physiotherapy*. 2010;6:60–9.
63. Pilutti LA, Platta ME, Motl RW, Latimer-Cheung AE. The safety of exercise training in multiple sclerosis: A systematic review. *Journal of the Neurological Sciences*. 2014;343:3–7.
64. Edwards T, Pilutti LA. The effect of exercise training in adults with multiple sclerosis with severe mobility disability: A systematic review and future research directions. *Multiple Sclerosis and Related Disorders*. 2017;16:31–9.
65. Arnold PB, McVey PP, Farrell WJ, Deurloo TM, Grasso MR. Functional electric stimulation: its efficacy and safety in improving pulmonary function and musculoskeletal fitness. *Archives of Physical Medicine and Rehabilitation*. 1992;73:665–8.
66. Dumville JC, Torgerson DJ, Hewitt CE. Reporting attrition in randomised controlled trials. *BMJ*. 2006;332:969–71.
67. Button KS, Ioannidis JPA, Mokrysz C, Nosek BA, Flint J, Robinson ESJ, et al. Power failure: why small sample size undermines the reliability of neuroscience. *Nature Reviews Neuroscience*. 2013;14:365–76.
68. Gluud LL. Bias in Clinical Intervention Research. *American Journal of Epidemiology*. 2006;163:493–501.
69. Rosenman R, Tennekoon V, Hill LG. Measuring bias in self-reported data. *Int J Behav Healthc Res*. 2011;2:320–32.

Evaluating Functional Electrical Stimulation (FES) Cycling on Cardiovascular, Musculoskeletal and Functional Outcomes in Adults with Multiple Sclerosis and Mobility Impairment: A systematic review

Jennifer B. Scally¹, Julien S. Baker¹, Jean Rankin¹, Linda Renfrew², Nicholas Sculthorpe¹

¹ Institute of Clinical Exercise and Health Science, School of Health and Life Sciences, University of the West of Scotland, South Lanarkshire, Scotland

² Douglas Grant Rehabilitation Unit, Ayrshire Central Hospital, Irvine, Scotland

Correspondence to: Jennifer B. Scally, Institute of Clinical Exercise and Health Science, School of Health and Life Sciences, University of the West of Scotland, South Lanarkshire, G72 0LH; jennifer.scally@uws.ac.uk; +44 (0)1698 283 100.